Expression and clinical value of G-protein coupled receptor 15 ligand in systemic lupus erythematosus

FANG Hua; LIU Xiang; CHEN Jiang; WANG Guobing

doi:10.7619/jcmp.20242016

Journal of Clinical Medicine in Practice > 2024 > 28(24): 57-62, 67. > DOI: 10.7619/jcmp.20242016

FANG Hua, LIU Xiang, CHEN Jiang, WANG Guobing. Expression and clinical value of G-protein coupled receptor 15 ligand in systemic lupus erythematosus[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 57-62, 67. DOI: 10.7619/jcmp.20242016

Citation:

PDF (2643 KB)

Expression and clinical value of G-protein coupled receptor 15 ligand in systemic lupus erythematosus

1.
Department of Laboratory Medicine, Yibin Traditional Chinese Medicine Hospital of Sichuan Province, Yibin, Sichuan, 644000
2.
Department of Laboratory Medicine, Yibin Second People's Hospital of Sichuan Province, Yibin, Sichuan, 644000

More Information

Received Date: May 14, 2024
Revised Date: August 10, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the expression level and clinical application value of G-protein coupled receptor 15 ligand (GPR15L) in patients with systemic lupus erythematosus (SLE).
Methods
In a retrospective cohort, real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of G-protein coupled receptor 15 (GPR15) mRNA and GPR15L mRNA in peripheral blood from 63 SLE patients (SLE group) and 57 healthy controls (control group). Enzyme-linked immunosorbent assay was employed to measure the serum GPR15L protein expression levels in the SLE group, control group, and 50 rheumatoid arthritis (RA) patients (disease control group). The relationship between serum GPR15L and laboratory indicators as well as therapeutic efficacy in SLE patients was analyzed. Receiver operating characteristic (ROC) curves were used to assess the diagnostic efficacy of serum GPR15 alone and combination with common autoantibody indicators for SLE. Multivariate Logistic regression analysis was conducted to explore the independent risk factors for SLE onset.
Results
Compared with the control group, the SLE group exhibited increased levels of GPR15 mRNA and GPR15L mRNA in peripheral blood (P=0.016 4, P < 0.000 1, respectively). The serum GPR15L expression in the SLE group was higher than that in the disease control group (P < 0.000 1). The serum GPR15L protein expression level in SLE patients was positively correlated with GPR15L mRNA and disease activity (r=0.301 3, P=0.016 4; r=0.361 7, P=0.003 6) and negatively correlated with complement C3 and C4 levels (r=-0.341 2, P=0.006 2; r=-0.338 4, P=0.006 7). The ROC curves showed that the area under the curve (AUC) for serum GPR15L in distinguishing the SLE group from the control group was 0.870 8, and the AUC for distinguishing the SLE group from the control group was 0.765 5. The diagnostic efficacy of serum GPR15L combined with anti-SSA for SLE was significantly improved, with an AUC of 0.895 2. Multivariate Logistic regression analysis revealed that elevated GPR15L protein and GPR15L mRNA were independent risk factors for SLE onset (P < 0.05).
Conclusion
The significant increase in serum GPR15L protein levels in SLE patients is closely related to SLE disease activity, and abnormal expression of GPR15L may play an important role in the pathogenesis of SLE.
- systemic lupus erythematosus,
- G-protein coupled receptor 15 ligand,
- chemokine,
- disease activity,
- autoantibodies

FullText(HTML)

References (20)

References

[1]	LAZAR S, KAHLENBERG J M. Systemic lupus erythematosus: new diagnostic and therapeutic approaches[J]. Annu Rev Med, 2023, 74: 339-352. doi: 10.1146/annurev-med-043021-032611
[2]	陈群, 严远飞, 陈数, 等. 系统性红斑狼疮合并心脏损害的相关危险因素分析[J]. 实用临床医药杂志, 2022, 26(1): 109-115. doi: 10.7619/jcmp.20212670
[3]	GERGIANAKI I, BORTOLUZZI A, BERTSIAS G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus[J]. Best Pract Res Clin Rheumatol, 2018, 32(2): 188-205. doi: 10.1016/j.berh.2018.09.004
[4]	CHEN C F, WU N, DUAN Q Q, et al. C10orf99 contributes to the development of psoriasis by promoting the proliferation of keratinocytes[J]. Sci Rep, 2018, 8(1): 8590. doi: 10.1038/s41598-018-26996-z
[5]	OKAMOTO Y, SHIKANO S. Emerging roles of a chemoattractant receptor GPR15 and ligands in pathophysiology[J]. Front Immunol, 2023, 14: 1179456. doi: 10.3389/fimmu.2023.1179456
[6]	ANDERSEN A M, LEI M K, BEACH S R H, et al. Inflammatory biomarker relationships with helper T cell GPR15 expression and cannabis and tobacco smoking[J]. J Psychosom Res, 2021, 141: 110326. doi: 10.1016/j.jpsychores.2020.110326
[7]	PETRI M, ORBAI A M, ALARCÓN G S, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686. doi: 10.1002/art.34473
[8]	ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581. doi: 10.1002/art.27584
[9]	ZHAO J, LIU X R, XU J B, et al. Elevated expression and activation of GPR15 in immune cells in Graves' disease[J]. Biomolecules, 2022, 12(12): 1899. doi: 10.3390/biom12121899
[10]	JEGODZINSKI L, SEZIN T, LOSER K, et al. The G protein-coupled receptor (GPR) 15 counteracts antibody-mediated skin inflammation[J]. Front Immunol, 2020, 11: 1858. doi: 10.3389/fimmu.2020.01858
[11]	FERNÁNDEZ-RUIZ J C, OCHOA-GONZÁLEZ F L, ZAPATA-ZÙÑIGA M, et al. GPR15 expressed in T lymphocytes from RA patients is involved in leukocyte chemotaxis to the synovium[J]. J Leukoc Biol, 2022, 112(5): 1209-1221. doi: 10.1002/JLB.3MA0822-263RR
[12]	TANG J S, STEPHENS R, LI Y Y, et al. Polyphenol and glucosinolate-derived AhR modulators regulate GPR15 expression on human CD4⁺ T cells[J]. J Nutr Biochem, 2023, 122: 109456. doi: 10.1016/j.jnutbio.2023.109456
[13]	ADAMCZYK A, PASTILLE E, KEHRMANN J, et al. GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer[J]. Cancer Res, 2021, 81(11): 2970-2982. doi: 10.1158/0008-5472.CAN-20-2133
[14]	KONKEL J E, ZHANG D F, ZANVIT P, et al. Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses[J]. Immunity, 2017, 46(4): 660-674. doi: 10.1016/j.immuni.2017.03.015
[15]	LI H, BOULOUGOURA A, ENDO Y, et al. Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies[J]. J Autoimmun, 2022, 132: 102870. doi: 10.1016/j.jaut.2022.102870
[16]	颜云霞, 张卓亚, 黄赛赛, 等. 系统性红斑狼疮患者外周血中γδT细胞及其主要功能亚群的变化及临床意义[J]. 实用临床医药杂志, 2024, 28(6): 88-93. doi: 10.7619/jcmp.20232969
[17]	THANOU A, JUPE E, PURUSHOTHAMAN M, et al. Clinical disease activity and flare in SLE: current concepts and novel biomarkers[J]. J Autoimmun, 2021, 119: 102615. doi: 10.1016/j.jaut.2021.102615
[18]	唐玉洁, 唐勇, 胡庆. 系统性红斑狼疮患者血清骨硬化蛋白及Dickkopf-1水平与病情严重程度的关系[J]. 实用临床医药杂志, 2023, 27(15): 35-39. doi: 10.7619/jcmp.20231208
[19]	SALAZAR-CAMARENA D C, PALAFOX-SÁNCHEZ C A, CRUZ A, et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients[J]. Sci Rep, 2020, 10(1): 6236. doi: 10.1038/s41598-020-63390-0
[20]	JIN H, ZHOU S H, YU Y, et al. Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China[J]. Lupus Sci Med, 2023, 10(1): e000819. doi: 10.1136/lupus-2022-000819

Cited By

Cited by

Periodical cited type(1)

荣会蓉，周金成，夏思，杨凡. 急性胰腺炎患儿血清中ATG7的表达及疾病进展的相关性研究. 现代消化及介入诊疗. 2023(05): 564-567+572 .

Other cited types(4)

Get Citation

PDF

XML

Article views (55) PDF downloads (3) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Expression and clinical value of G-protein coupled receptor 15 ligand in systemic lupus erythematosus

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(4)

Catalog

Export File

Citation

Format

Content